Short answer
Cullinan Therapeutics, Inc. (CGEM) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$49M
- +2.4% YoY · +8.0% QoQ
Source: XBRL data from the Cullinan Therapeutics, Inc. (CGEM) Q3 2026 10-Q on SEC EDGAR. USD.
Cullinan Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no product sales, unchanged from Q3 2025
- R&D expense $40.2M vs $42.0M YoY, G&A $12.4M vs $13.6M
- Best pipeline growth: CLN-978 R&D $9.8M vs $5.3M YoY
- Cash, equivalents, and short-term investments $289.6M, long-term investments and interest receivable $24.2M
- Operating cash outflow $127.3M, cash expected to fund operations at least twelve months, additional capital may be needed
Risk Factors
- Newly added SEC compliance risk: non-affiliate market value exceeded $700 million on June 30, 2026
- Reporting transition: SRC status ends after December 31, 2026, with accommodations continuing for 2027 filings
- Regulatory burden: accelerated-filer status could require Section 404(b) auditor attestation beginning December 31, 2027
- Financial risk: additional reporting requirements expected to increase legal, accounting and compliance costs
- Operational risk: expanded public-company obligations could divert management attention from operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cullinan Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.